
KZR Stock Forecast & Price Target
KZR Analyst Ratings
Bulls say
Kezar Life Sciences Inc. has garnered a positive outlook due to the lifting of the partial clinical hold on its therapeutic candidate, Zetomipzomib (KZR-616), for the treatment of autoimmune hepatitis (AIH), which enhances investor confidence in its risk-benefit profile. The potential full removal of the clinical hold in lupus nephritis (LN) could significantly bolster investor confidence and facilitate eventual clinical uptake if approved, presenting an opportunity for market expansion. These developments suggest a favorable trajectory for the company's pipeline and potential commercial viability of its assets in addressing significant unmet medical needs in both autoimmunity and cancer.
Bears say
Kezar Life Sciences Inc. is currently facing significant challenges due to its clinical-stage status, which inherently carries high risk and uncertainty regarding the success of its product candidates, Zetomipzomib (KZR-616) and KZR-261. The company has reported limited progress in advancing its pipeline, coupled with escalating research and development expenditures that could strain financial resources, especially if trials do not yield favorable outcomes. Additionally, the lack of diversified revenue streams and reliance on breakthrough results further contribute to a cautious sentiment regarding the company's future financial performance.
This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KZR Analyst Forecast & Price Prediction
Start investing in KZR
Order type
Buy in
Order amount
Est. shares
0 shares